{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:41:58Z","timestamp":1789731718764,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Biologic therapies represent transformative interventions for severe asthma; however, comprehensive integration of clinical effectiveness with economic evidence across real-world populations remains incomplete. This systematic review synthesizes both domains to support clinical and policy decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic literature search (PubMed, Scopus; 2014\u20132024) following PRISMA 2020 guidelines with prospective PROSPERO registration (CRD420251153385). Eligible studies evaluated biologic therapies in real-world asthma populations, reporting clinical outcomes (exacerbations, lung function, asthma control, quality of life) and economic measures (costs, ICER, healthcare resource utilization). GRADE methodology assessed evidence certainty; risk of bias evaluated using RoB 2 (RCTs) and ROBINS-I (observational studies).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-seven studies (25 observational, 2 RCTs; 59,958 patients) evaluated omalizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911), mepolizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), benralizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094), dupilumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), tezepelumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), reslizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) and multiple biologic drugs comparatively (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094). All agents showed exacerbation reductions (46\u201386%), with 48\u201381% of previously exacerbating patients achieving exacerbation-free status. Hospitalizations decreased 57\u201385% and emergency department visits reduced 52\u201372%. Oral corticosteroid-dependent patients decreased 53\u201367%, representing substantial safety and quality-of-life benefits. Healthcare resource utilization reductions generated cost offsets of \u20ac1,181\u20132469 per patient annually, achieving favorable cost-effectiveness (\u20ac602\u20132244 per exacerbation avoided). High treatment persistence (51\u201354 months) and adherence (70\u201394.6%) exceeded conventional therapies. Significant methodological limitations were evident: 80.8% observational studies had serious bias risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biologic therapies achieve substantial clinical benefits and favorable economic value through healthcare cost offsets. Precision medicine approaches and early response assessment optimize patient selection and clinical outcomes in severe asthma management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00408-026-00903-0","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:38:59Z","timestamp":1781602739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review"],"prefix":"10.1007","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-4340","authenticated-orcid":false,"given":"Cataldo","family":"Procacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Gualano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonarda","family":"Maurmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"903_CR1","doi-asserted-by":"publisher","first-page":"4S","DOI":"10.1378\/chest.130.1_suppl.4S","volume":"130","author":"SS Braman","year":"2006","unstructured":"Braman SS (2006) The global burden of asthma. Chest 130:4S\u201312. https:\/\/doi.org\/10.1378\/chest.130.1_suppl.4S","journal-title":"Chest"},{"key":"903_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.18553\/JMCP.2023.29.7.825","volume":"29","author":"A Burnette","year":"2023","unstructured":"Burnette A, Wang Y, Rane PB et al (2023) Incremental cost burden among patients with severe uncontrolled asthma in the United States. J Manag Care Spec Pharm 29:825\u2013834. https:\/\/doi.org\/10.18553\/JMCP.2023.29.7.825","journal-title":"J Manag Care Spec Pharm"},{"key":"903_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/RCCM.201901-0016OC","volume":"200","author":"M Yaghoubi","year":"2019","unstructured":"Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M (2019) The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med 200:1102\u20131112. https:\/\/doi.org\/10.1164\/RCCM.201901-0016OC","journal-title":"Am J Respir Crit Care Med"},{"key":"903_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12890-023-02685-0\/TABLES\/5","volume":"23","author":"X Yang","year":"2023","unstructured":"Yang X, Zhang T, Yang X, Jiang J, He Y, Wang P (2023) Medical resource utilization and the associated costs of asthma in China: a 1-year retrospective study. BMC Pulm Med 23:1\u201310. https:\/\/doi.org\/10.1186\/S12890-023-02685-0\/TABLES\/5","journal-title":"BMC Pulm Med"},{"key":"903_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12931-018-0855-3\/FIGURES\/3","volume":"19","author":"C Janson","year":"2018","unstructured":"Janson C, Lisspers K, St\u00e4llberg B et al (2018) Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids\u2014a Swedish observational cohort study (PACEHR). Respir Res 19:1\u20138. https:\/\/doi.org\/10.1186\/S12931-018-0855-3\/FIGURES\/3","journal-title":"Respir Res"},{"key":"903_CR6","doi-asserted-by":"publisher","unstructured":"Gonzalez-Uribe V, Romero-Tapia SJ, Castro-Rodriguez JA (2023) Asthma phenotypes in the era of personalized medicine. J Clin Med 12. https:\/\/doi.org\/10.3390\/JCM12196207","DOI":"10.3390\/JCM12196207"},{"key":"903_CR7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jval.2019.03.016","volume":"22","author":"S Ehteshami-Afshar","year":"2019","unstructured":"Ehteshami-Afshar S, Zafari Z, Hamidi N, FitzGerald JM, Lynd L, Sadatsafavi M (2019) A systematic review of decision-analytic models for evaluating cost-effectiveness of asthma interventions. Value Health 22:1070\u20131082. https:\/\/doi.org\/10.1016\/j.jval.2019.03.016","journal-title":"Value Health"},{"key":"903_CR8","doi-asserted-by":"publisher","unstructured":"Lee LK, Ramakrishnan K, Safioti G, Ariely R, Schatz M (2020) Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma. BMJ Open Respir Res 7. https:\/\/doi.org\/10.1136\/BMJRESP-2019-000534","DOI":"10.1136\/BMJRESP-2019-000534"},{"key":"903_CR9","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4321\/S1886-36552014000400008","volume":"12","author":"YV Yong","year":"2014","unstructured":"Yong YV, Shafie AA (2014) Economic evaluation of enhanced asthma management: a systematic review. Pharm Pract (Internet) 12:0\u20130. https:\/\/doi.org\/10.4321\/S1886-36552014000400008","journal-title":"Pharm Pract (Internet)"},{"key":"903_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3109\/02770903.2014.999283","volume":"52","author":"J Dom\u00ednguez-Ortega","year":"2015","unstructured":"Dom\u00ednguez-Ortega J, Phillips-Angl\u00e9s E, Barranco P, Quirce S (2015) Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma 52:529\u2013537. https:\/\/doi.org\/10.3109\/02770903.2014.999283","journal-title":"J Asthma"},{"key":"903_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/J.JVAL.2020.01.016","volume":"23","author":"DA Marshall","year":"2020","unstructured":"Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips K, Ijzerman M (2020) Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling. Value Health 23:566. https:\/\/doi.org\/10.1016\/J.JVAL.2020.01.016","journal-title":"Value Health"},{"key":"903_CR12","doi-asserted-by":"publisher","unstructured":"Fitzpatrick AM, Moore WC (2017) Severe asthma phenotypes\u2014how should they guide evaluation and treatment? J Allergy Clinical Immunol: In Practice. 5:901\u2013908. https:\/\/doi.org\/10.1016\/J.JAIP.2017.05.015","DOI":"10.1016\/J.JAIP.2017.05.015"},{"key":"903_CR13","doi-asserted-by":"publisher","unstructured":"Fl\u00f3rez-Tanus \u00c1, Parra D, Zakzuk J, Caraballo L, Alvis-Guzm\u00e1n N (2018) Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J 11. https:\/\/doi.org\/10.1186\/s40413-018-0205-4","DOI":"10.1186\/s40413-018-0205-4"},{"key":"903_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14737167.2023.2221435","volume":"23","author":"S Alves","year":"2023","unstructured":"Alves S, Rufo JC, Crispim J (2023) Economic evaluation of biological treatments in patients with severe asthma: a systematic review. Expert Rev Pharmacoecon Outcomes Res 23:733\u2013747. https:\/\/doi.org\/10.1080\/14737167.2023.2221435","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"903_CR15","unstructured":"In: Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report Prepared for 2018."},{"key":"903_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/JAA.S502216","volume":"18","author":"JA Buendia","year":"2025","unstructured":"Buendia JA, Acuna-Cordero R, Rodriguez-Martinez CE (2025) Economic evaluation of mepolizumab as add-on therapy to standard care in severe eosinophilic asthma: a cost-effectiveness analysis in Colombia. J Asthma Allergy 18:211. https:\/\/doi.org\/10.2147\/JAA.S502216","journal-title":"J Asthma Allergy"},{"key":"903_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/S40273-018-0726-2","volume":"37","author":"R Perry","year":"2019","unstructured":"Perry R, Braileanu G, Palmer T, Stevens P (2019) The economic burden of pediatric asthma in the United States: literature review of current evidence. PharmacoEconomics 37:155\u2013167. https:\/\/doi.org\/10.1007\/S40273-018-0726-2","journal-title":"PharmacoEconomics"},{"key":"903_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/JAA.S452747","volume":"18","author":"I Gouia","year":"2025","unstructured":"Gouia I, Joulain F, Zhang Y, Morgan CL, Khan AH (2025) Clinical burden and healthcare resource use of asthma in children in the UK. J Asthma Allergy 18:161\u2013171. https:\/\/doi.org\/10.2147\/JAA.S452747","journal-title":"J Asthma Allergy"},{"key":"903_CR19","first-page":"A11","volume":"2","author":"LY Wang","year":"2004","unstructured":"Wang LY, Zhong Y, Wheeler L (2004) Direct and indirect costs of asthma in school-age children. Prev Chronic Dis 2:A11","journal-title":"Prev Chronic Dis"},{"key":"903_CR20","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/BMJ.N71","DOI":"10.1136\/BMJ.N71"},{"key":"903_CR21","unstructured":"Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis | Cochrane. Accessed: November 13 (2025) https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-03"},{"key":"903_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/BMJ.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/BMJ.39489.470347.AD","journal-title":"BMJ"},{"key":"903_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366. https:\/\/doi.org\/10.1136\/BMJ.L4898","DOI":"10.1136\/BMJ.L4898"},{"key":"903_CR24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","volume":"10","author":"DJ Jackson","year":"2022","unstructured":"Jackson DJ, Burhan H, Menzies-Gow A et al (2022) Benralizumab effectiveness in severe asthma is independent of previous biologic use. J Allergy Clin Immunology: Pract 10:1534\u20131544e4. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.014","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"903_CR25","doi-asserted-by":"publisher","unstructured":"Humbert M, Bourdin A, Taill\u00e9 C et al (2022) Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J 60. https:\/\/doi.org\/10.1183\/13993003.03130-2021","DOI":"10.1183\/13993003.03130-2021"},{"key":"903_CR26","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1007\/S12325-024-02967-X","volume":"41","author":"RO Al-Lehebi","year":"2024","unstructured":"Al-Lehebi RO, Al Ahmad M, Maturu VN et al (2024) Real-world effectiveness of mepolizumab in severe asthma: results from the multi-country, self-controlled Nucala Effectiveness Study (NEST). Adv Ther 41:4008\u20134031. https:\/\/doi.org\/10.1007\/S12325-024-02967-X","journal-title":"Adv Ther"},{"key":"903_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/J.PULMOE.2020.03.001","volume":"27","author":"A Arrobas","year":"2021","unstructured":"Arrobas A, Barbosa MP, Rabiais S, Vandewalle B, F\u00e9lix J (2021) Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients. Pulmonology 27:124\u2013133. https:\/\/doi.org\/10.1016\/J.PULMOE.2020.03.001","journal-title":"Pulmonology"},{"key":"903_CR28","doi-asserted-by":"publisher","unstructured":"Chen HC, Huang C, Da, Chang E, Kuo HP (2016) Efficacy of omalizumab (Xolair\u00ae) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulm Med 16. https:\/\/doi.org\/10.1186\/S12890-015-0156-2","DOI":"10.1186\/S12890-015-0156-2"},{"key":"903_CR29","doi-asserted-by":"publisher","first-page":"e0183869","DOI":"10.1371\/JOURNAL.PONE.0183869","volume":"12","author":"M Bhutani","year":"2017","unstructured":"Bhutani M, Yang WH, H\u00e9bert J, De Takacsy F, Stril JL (2017) The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. PLoS ONE 12:e0183869. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0183869","journal-title":"PLoS ONE"},{"key":"903_CR30","doi-asserted-by":"publisher","unstructured":"Niven RM, Saralaya D, Chaudhuri R et al (2016) Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open 6. https:\/\/doi.org\/10.1136\/BMJOPEN-2016-011857","DOI":"10.1136\/BMJOPEN-2016-011857"},{"key":"903_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","volume":"128","author":"Y Chung","year":"2022","unstructured":"Chung Y, Katial R, Mu F et al (2022) Real-world effectiveness of benralizumab: results from the ZEPHYR 1 study. Annals Allergy Asthma Immunol 128:669\u2013676e6. https:\/\/doi.org\/10.1016\/j.anai.2022.02.017","journal-title":"Asthma Immunol"},{"key":"903_CR32","doi-asserted-by":"publisher","unstructured":"Padilla-Galo A, Moya Carmona I, Aus\u00edn P et al (2023) Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. Respir Res 24. https:\/\/doi.org\/10.1186\/S12931-023-02539-7","DOI":"10.1186\/S12931-023-02539-7"},{"key":"903_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J et al (2016) Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388:31\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(16)30307-5","journal-title":"Lancet"},{"key":"903_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.anai.2023.05.028","volume":"131","author":"A Menzies-Gow","year":"2023","unstructured":"Menzies-Gow A, Bourdin A, Chupp G et al (2023) Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: the NAVIGATOR study. Annals Allergy Asthma Immunol 131:343\u2013348e2. https:\/\/doi.org\/10.1016\/j.anai.2023.05.028","journal-title":"Asthma Immunol"},{"key":"903_CR35","doi-asserted-by":"publisher","unstructured":"Bagnasco D, Povero M, Pradelli L et al (2024) Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organ J 14. https:\/\/doi.org\/10.1016\/J.WAOJOU.2021.100509","DOI":"10.1016\/J.WAOJOU.2021.100509"},{"key":"903_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.anai.2024.06.033","volume":"133","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Silver J, Packnett E, Lew CR, Robles Y, Deb A (2024) Real-world unified airway benefits of mepolizumab: effectiveness in patients with asthma and comorbid nasal polyps. Annals Allergy Asthma Immunol 133:422\u2013429e2. https:\/\/doi.org\/10.1016\/j.anai.2024.06.033","journal-title":"Annals Allergy Asthma Immunol"},{"key":"903_CR37","doi-asserted-by":"publisher","unstructured":"Carpagnano GE, Resta E, Povero M et al (2021) Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Sci Rep 11. https:\/\/doi.org\/10.1038\/S41598-021-84895-2","DOI":"10.1038\/S41598-021-84895-2"},{"key":"903_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/S41669-019-0117-4","volume":"3","author":"LM Entrenas Costa","year":"2019","unstructured":"Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG et al (2019) Economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study. PharmacoEconomics Open 3:333. https:\/\/doi.org\/10.1007\/S41669-019-0117-4","journal-title":"PharmacoEconomics - Open 2019"},{"key":"903_CR39","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/J.CHEST.2020.11.060","volume":"159","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Peters SP, Hill TD et al (2021) Clinical outcomes and health-care resource use associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice. Chest 159:1734\u20131746. https:\/\/doi.org\/10.1016\/J.CHEST.2020.11.060","journal-title":"Chest"},{"key":"903_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/S11096-014-0034-7","volume":"37","author":"C Gouder","year":"2015","unstructured":"Gouder C, West LM, Montefort S (2015) The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm 37:36\u201343. https:\/\/doi.org\/10.1007\/S11096-014-0034-7","journal-title":"Int J Clin Pharm"},{"key":"903_CR41","doi-asserted-by":"publisher","unstructured":"Jahnz-R\u00f3zyk K, Lis J, Warcho\u0142 M, Kucharczyk A (2018) Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulm Med 18. https:\/\/doi.org\/10.1186\/S12890-018-0610-Z","DOI":"10.1186\/S12890-018-0610-Z"},{"key":"903_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","volume":"7","author":"TB Casale","year":"2019","unstructured":"Casale TB, Luskin AT, Busse W et al (2019) Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunology: Pract 7:156\u2013164e1. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.043","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"903_CR43","doi-asserted-by":"publisher","unstructured":"Chapman KR, Cogger K, Arthurs E et al (2024) Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study. Allergy Asthma Clin Immunol 20. https:\/\/doi.org\/10.1186\/S13223-023-00863-7","DOI":"10.1186\/S13223-023-00863-7"},{"key":"903_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/PED.12936","volume":"58","author":"H Yoshikawa","year":"2016","unstructured":"Yoshikawa H, Iwata M, Matsuzaki H et al (2016) Impact of omalizumab on medical cost of childhood asthma in Japan. Pediatr Int 58:425\u2013428. https:\/\/doi.org\/10.1111\/PED.12936","journal-title":"Pediatr Int"},{"key":"903_CR45","doi-asserted-by":"publisher","unstructured":"Padilla-Galo A, Garc\u00eda-Ruiz AJ, Levy Abitbol RC et al (2021) Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respir Res 22. https:\/\/doi.org\/10.1186\/S12931-021-01758-0","DOI":"10.1186\/S12931-021-01758-0"},{"key":"903_CR46","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1016\/J.JAIP.2020.06.012","volume":"8","author":"G Mosnaim","year":"2020","unstructured":"Mosnaim G, Huang H, Ariely R et al (2020) Clinical and economic outcomes in patients with persistent asthma who attain healthcare effectiveness and data information set measures. J Allergy Clin Immunol Pract 8:3443\u20133454e2. https:\/\/doi.org\/10.1016\/J.JAIP.2020.06.012","journal-title":"J Allergy Clin Immunol Pract"},{"key":"903_CR47","doi-asserted-by":"publisher","unstructured":"Gyawali B, Georas SN, Khurana S (2025) Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev 34. https:\/\/doi.org\/10.1183\/16000617.0088-2024","DOI":"10.1183\/16000617.0088-2024"},{"key":"903_CR48","doi-asserted-by":"publisher","unstructured":"Chen CY, Wu KH, Guo BC et al (2023) Personalized medicine in severe asthma: from biomarkers to biologics. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/IJMS25010182","DOI":"10.3390\/IJMS25010182"},{"key":"903_CR49","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.rmed.2009.01.008","volume":"103","author":"A Pipet","year":"2009","unstructured":"Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A (2009) Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respir Med 103:800\u2013812. https:\/\/doi.org\/10.1016\/j.rmed.2009.01.008","journal-title":"Respir Med"},{"key":"903_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L et al (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 9:30. https:\/\/doi.org\/10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"key":"903_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/JAA.S354062","volume":"15","author":"F Hardtstock","year":"2022","unstructured":"Hardtstock F, Krieger J, Wilke T et al (2022) Use of biologic therapies in the treatment of asthma\u2014a comparative real world data analysis on healthcare resource utilization and costs before and after therapy initiation. J Asthma Allergy 15:407\u2013418. https:\/\/doi.org\/10.2147\/JAA.S354062","journal-title":"J Asthma Allergy"},{"key":"903_CR52","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1080\/02770903.2022.2139718","volume":"60","author":"M Mareque","year":"2023","unstructured":"Mareque M, Climente M, Martinez-Moragon E et al (2023) Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain. J Asthma 60:1210\u20131220. https:\/\/doi.org\/10.1080\/02770903.2022.2139718","journal-title":"J Asthma"},{"key":"903_CR53","doi-asserted-by":"publisher","unstructured":"Bagnasco D, Povero M, Pradelli L et al (2021) Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organ J 14. https:\/\/doi.org\/10.1016\/j.waojou.2021.100509","DOI":"10.1016\/j.waojou.2021.100509"},{"key":"903_CR54","doi-asserted-by":"publisher","first-page":"2532973","DOI":"10.1080\/25310429.2025.2532973","volume":"31","author":"KEJ H\u00e5kansson","year":"2025","unstructured":"H\u00e5kansson KEJ, Ibsen R, Steen Krogh N et al (2025) Financial burden of productivity loss in severe asthma and impact of biologic therapy. Pulmonology 31:2532973. https:\/\/doi.org\/10.1080\/25310429.2025.2532973","journal-title":"Pulmonology"},{"key":"903_CR55","unstructured":"Rapporto OsMed (2024) sull\u2019uso dei farmaci in Italia. Accessed: December 29, 2025. https:\/\/www.aifa.gov.it\/-\/rapporto-osmed-2024-uso-farmaci-italia"},{"key":"903_CR56","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/ALL.15197","volume":"77","author":"J Corren","year":"2022","unstructured":"Corren J, Pham TH, Garcia Gil E et al (2022) Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy 77:1786\u20131796. https:\/\/doi.org\/10.1111\/ALL.15197","journal-title":"Allergy"},{"key":"903_CR57","doi-asserted-by":"publisher","unstructured":"Pelaia C, Pelaia G, Crimi C, Maglio A, Gallelli L, Terracciano R, Vatrella A (2021) Tezepelumab: a potential new biological therapy for severe refractory asthma. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/IJMS22094369","DOI":"10.3390\/IJMS22094369"},{"key":"903_CR58","doi-asserted-by":"publisher","unstructured":"Chiu CJ, Huang MT (2021) Asthma in the precision medicine era: biologics and probiotics. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/IJMS22094528","DOI":"10.3390\/IJMS22094528"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00903-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00903-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00903-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:39:09Z","timestamp":1781602749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00903-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00903-0","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"37"}}